Among the significant analyses, 70% of the study revealed that CAV1 and CAV2 were all significantly downregulated in most tumor types, especially in BC, lung cancer, ovarian cancer, prostate cancer, bladder cancer, and sarcoma cancer. This evidence concerns the gene CAV1 and ovarian carcinoma.